Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.55 |
| ▸ | PDE4A | P27815 | 4/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.55 |
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.44 |
| ▸ | EEF2K | O00418 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 3/20 | 0.39 |
| ▸ | JAK1 | P23458 | 3/20 | 0.39 |
| ▸ | JAK3 | P52333 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7464187 | 0.82 | PDE4A (0.65) | CYP3A4PMP22MAPK1ADORA2APDE4A | |
| SCHEMBL9842568 | 0.81 | PDE4A (0.59) | CYP3A4PMP22MAPK1ADORA2APDE4A | |
| SCHEMBL9842833 | 0.80 | ALDH1A1 (0.67) | MAPK1ADORA2APDE4APDE4BPDE4C | |
| SCHEMBL9842911 | 0.79 | MEN1 (0.62) | MAPK1ADORA2APDE4APDE4BPDE4C | |
| SCHEMBL9842775 | 0.78 | SMN1; SMN2 (0.47) | CYP3A4PMP22MAPK1ADORA2APDE4A | |
| SCHEMBL9842882 | 0.78 | MEN1 (0.60) | MAPK1ADORA2APDE4APDE4BPDE4C | |
| SCHEMBL9615238 | 0.77 | SMN1; SMN2 (0.44) | CYP3A4PMP22MAPK1ADORA2APDE4A | |
| Theobromine SCHEMBL3184 | 0.77 | CYP3A4 (1.00) | CYP3A4PMP22MAPK1ADORA2APDE4A | |
| Theobromine SCHEMBL11599459 | 0.77 | CYP3A4 (1.00) | CYP3A4PMP22MAPK1ADORA2APDE4A | |
| Theobromine SCHEMBL1690622 | 0.77 | CYP3A4 (1.00) | CYP3A4PMP22MAPK1ADORA2APDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187728-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20230067237-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230067237-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11370792-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-11370792-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-20180370972-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2018-12-27 | — | — | US | disclosed |
| EP-3389664-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | Raze Therapeutics Inc. (US) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017106352-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017106352-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| EP-0430025-A2 | Xanthine compound, method for preparing thereof, and a pharmaceutical composition comprising the same | HOKURIKU PHARMACEUTICAL CO., LTD. (JP) | 1991-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187728-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | MTHFD2, MTHFD1, NUDT15 | CYP3A4 830/4885PMP22 1703/4885MAPK1 3354/4885 |
| US-11370792-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | MTHFD2, MTHFD1, NUDT15 | CYP3A4 830/4885PMP22 1703/4885MAPK1 3354/4885 |
| US-20230067237-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | MTHFD2, MTHFD1, NUDT15 | CYP3A4 830/4885PMP22 1703/4885MAPK1 3354/4885 |
| US-20180370972-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | MTHFD2, MTHFD1, NUDT15 | CYP3A4 830/4885PMP22 1703/4885MAPK1 3354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.